Priaxon names chief development officer
This article was originally published in Scrip
Priaxon, a privately held pharmaceutical company developing novel small-molecule agents for the modulation of protein-protein interactions, has named Dr Constance Hoefer chief development officer. Prior to joining the Munich, Germany-based firm Dr Hoefer was vice-president and head of non-clinical development at Medigene. She will be responsible for non-clinical and early clinical development projects at Priaxon.